Cargando…

Forcible destruction of severely misfolded mammalian glycoproteins by the non-glycoprotein ERAD pathway

Glycoproteins and non-glycoproteins possessing unfolded/misfolded parts in their luminal regions are cleared from the endoplasmic reticulum (ER) by ER-associated degradation (ERAD)-L with distinct mechanisms. Two-step mannose trimming from Man(9)GlcNAc(2) is crucial in the ERAD-L of glycoproteins. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Ninagawa, Satoshi, Okada, Tetsuya, Sumitomo, Yoshiki, Horimoto, Satoshi, Sugimoto, Takehiro, Ishikawa, Tokiro, Takeda, Shunichi, Yamamoto, Takashi, Suzuki, Tadashi, Kamiya, Yukiko, Kato, Koichi, Mori, Kazutoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657166/
https://www.ncbi.nlm.nih.gov/pubmed/26572623
http://dx.doi.org/10.1083/jcb.201504109
Descripción
Sumario:Glycoproteins and non-glycoproteins possessing unfolded/misfolded parts in their luminal regions are cleared from the endoplasmic reticulum (ER) by ER-associated degradation (ERAD)-L with distinct mechanisms. Two-step mannose trimming from Man(9)GlcNAc(2) is crucial in the ERAD-L of glycoproteins. We recently showed that this process is initiated by EDEM2 and completed by EDEM3/EDEM1. Here, we constructed chicken and human cells simultaneously deficient in EDEM1/2/3 and analyzed the fates of four ERAD-L substrates containing three potential N-glycosylation sites. We found that native but unstable or somewhat unfolded glycoproteins, such as ATF6α, ATF6α(C), CD3-δ–ΔTM, and EMC1, were stabilized in EDEM1/2/3 triple knockout cells. In marked contrast, degradation of severely misfolded glycoproteins, such as null Hong Kong (NHK) and deletion or insertion mutants of ATF6α(C), CD3-δ–ΔTM, and EMC1, was delayed only at early chase periods, but they were eventually degraded as in wild-type cells. Thus, higher eukaryotes are able to extract severely misfolded glycoproteins from glycoprotein ERAD and target them to the non-glycoprotein ERAD pathway to maintain the homeostasis of the ER.